152 related articles for article (PubMed ID: 36819801)
1. Diagnostic accuracy of SATB2 in identifying primary and metastatic colorectal carcinoma: a comparative immunohistochemical study.
Elnady MS; Eltatawy FA; Nosseir AG; Zamzam YA; El-Guindya DM
Ecancermedicalscience; 2022; 16():1491. PubMed ID: 36819801
[TBL] [Abstract][Full Text] [Related]
2. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
[TBL] [Abstract][Full Text] [Related]
3. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
Dabir PD; Svanholm H; Christiansen JJ
APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
[TBL] [Abstract][Full Text] [Related]
4. Dual Stain With SATB2 and CK20/Villin Is Useful to Distinguish Colorectal Carcinomas From Other Tumors.
Li Z; Rock JB; Roth R; Lehman A; Marsh WL; Suarez A; Frankel WL
Am J Clin Pathol; 2018 Feb; 149(3):241-246. PubMed ID: 29471325
[TBL] [Abstract][Full Text] [Related]
5. Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic Pitfall.
Neri G; Arpa G; Guerini C; Grillo F; Lenti MV; Giuffrida P; Furlan D; Sessa F; Quaquarini E; Viglio A; Ubezio C; Pasini A; Ferrero S; Sampietro G; Ardizzone S; Latella G; Mescoli C; Rugge M; Zingone F; Barresi V; Ciccocioppo R; Pedrazzoli P; Corazza GR; Luinetti O; Solcia E; Paulli M; Di Sabatino A; Vanoli A
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33228145
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.
Lee JA; Seo MK; Yoo SY; Cho NY; Kwak Y; Lee K; Kim JH; Kang GH
Virchows Arch; 2022 Mar; 480(3):543-555. PubMed ID: 35029777
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
[TBL] [Abstract][Full Text] [Related]
8. Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers.
Lee JA; Park HE; Jin HY; Jin L; Cho NY; Bae JM; Kim JH; Kang GH
Ann Diagn Pathol; 2024 Aug; 71():152289. PubMed ID: 38555678
[TBL] [Abstract][Full Text] [Related]
9. SATB2 Versus CDX2: A Battle Royale for Diagnostic Supremacy in Mucinous Tumors.
Brettfeld SM; Ramos BD; Berry RS; Martin DR; Hanson JA
Arch Pathol Lab Med; 2019 Sep; 143(9):1119-1125. PubMed ID: 30838879
[TBL] [Abstract][Full Text] [Related]
10. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
11. Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms.
Li Z; Roth R; Rock JB; Lehman A; Marsh WL; Suarez A; Frankel WL
Am J Clin Pathol; 2017 May; 147(5):484-491. PubMed ID: 28340228
[TBL] [Abstract][Full Text] [Related]
12. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
[TBL] [Abstract][Full Text] [Related]
13. Impact of Neoadjuvant Chemotherapy on SATB2 Expression in Colorectal Carcinomas: SATB2 Positivity is Preserved in Most Cases, but Down-Expressed in Effective Cases of Chemotherapy.
Asahina Y; Hashimoto H; Aihara M; Noie T; Morikawa T
Int J Surg Pathol; 2023 Feb; 31(1):46-55. PubMed ID: 35343276
[TBL] [Abstract][Full Text] [Related]
14. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas.
Magnusson K; de Wit M; Brennan DJ; Johnson LB; McGee SF; Lundberg E; Naicker K; Klinger R; Kampf C; Asplund A; Wester K; Gry M; Bjartell A; Gallagher WM; Rexhepaj E; Kilpinen S; Kallioniemi OP; Belt E; Goos J; Meijer G; Birgisson H; Glimelius B; Borrebaeck CA; Navani S; Uhlén M; O'Connor DP; Jirström K; Pontén F
Am J Surg Pathol; 2011 Jul; 35(7):937-48. PubMed ID: 21677534
[TBL] [Abstract][Full Text] [Related]
15. Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups.
Schmitt M; Silva M; Konukiewitz B; Lang C; Steiger K; Halfter K; Engel J; Jank P; Pfarr N; Wilhelm D; Foersch S; Denkert C; Tschurtschenthaler M; Weichert W; Jesinghaus M
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944797
[TBL] [Abstract][Full Text] [Related]
16. SATB2 Is Superior to CDX2 in Distinguishing Signet Ring Cell Carcinoma of the Upper Gastrointestinal Tract and Lower Gastrointestinal Tract.
Ma C; Lowenthal BM; Pai RK
Am J Surg Pathol; 2018 Dec; 42(12):1715-1722. PubMed ID: 30212392
[TBL] [Abstract][Full Text] [Related]
17. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine.
Lin F; Shi J; Zhu S; Chen Z; Li A; Chen T; Wang HL; Liu H
Arch Pathol Lab Med; 2014 Aug; 138(8):1015-26. PubMed ID: 24437456
[TBL] [Abstract][Full Text] [Related]
18. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Immunophenotypic Panel to Differentiate Upper From Lower Gastrointestinal Adenocarcinomas: Analysis of New and Traditional Markers.
Chauhan A; Sanchez-Avila M; Manivel J; Dachel S; Larson W; Hanson B; Gravely A; Mesa H
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):13-19. PubMed ID: 33295746
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
